Not-for-Profit

Research with a real world agenda

Tesla Minds' Simulation Systems Research Department is the successor of Simulation Systems Research Corporation Ltd (SSRC) which was founded in 1997 by our present chairman Stefan Gollasch as an organization dedicated to the promotion of research. Our vision is to further scientific understanding of the world humankind is living in and to promote such research that promises real improvements for everyday life and the environment. We believe humankind is at a crossroads now and commit ourselves to work actively towards a positive change.

SSRC logoPragmatic Approach

Our belief is that successful research pushes the limit of what we know, what we understand and what we could apply in a real world context. While the subjects of research differ wildly, from how miniscule proteins affect the properties of the food we eat and the medicine we take, up to understanding global climate change, all of these have one thing in common: gaining knowledge. We provide digital solutions that employ artificial intelligence for the detection of patterns and interdependencies in conventionally obtained data and for the replacement of many laboratory experiments by the computer simulation of the research subject.

At the center of our strategy is the development of a super-simulator that will create a perfect virtual image that will mimic real world subjects 1:1, accurate in detail down to nano-scale and subatomic levels, and in effect will make many (real) experiments redundant. While our work in the next years will be driven by this vision, we will consecutively develop practical solutions and technologies to enhance research capability step by step.

Not-for-profit

We define ourselves as a not-for-profit organisation. That isn't to say that we think our work won't turn a profit. Just the opposite is true. We believe strongly that successful research and its commercialization that results in innovative products and processes will generate a high yield from patents and licenses. The term not-for-profit stands for our commitment to reinvest 100% of our profits again into research and development.

Consequently our shareholders do not take a financial interest in the company. As a rule each shareholder is alloted one single share only that provides for a single vote and a seat in our research council. This assembly directs our research focus, determines the projects we will undertake, and has a general controlling function. Membership in the company and research council is by invitation, normally in recognition of personal achievements in research and its promotion.

Investors in Research

Research cannot be done without financial backing. Our business model is comprised of three stages: first, research required as a prerequisite for a new product or process; second, prototype development and patenting; and third, commercial product development and licensing. Depending on the stage of a given project, we rely on two different sources of investment. For initial development we issue income debentures; this capital is used to complete research until proof of concept and for initial prototyping; capital raised by debentures is not allocated to a specific project but managed as a fund for financing initial development in general. Debenture holders will receive interest plus a share of royalties from patenting and licensing successful products and processes; given our portfolio of technologies that will emerge from our current research, we expect that the return on investment will outperform any commercial investment fund.

The commercialization of research, including commercial product development and licensing, relies on financing by venture capital. Generally, each research project that enters the commercialization phase will result in a joint-venture or an independent business, in which all project partners receive respective shares.

In short our role is that of a specialized holding that identifies research projects, provides initial financing and coordination of research effort, cooperates with venture capital funds for the commercialization of research, and reinvests any proceedings from successful ventures again in research and development.

*